Navigation Links
Afid Therapeutics Obtains Positive Evaluation of its Triple Mode,Viral Sequestration Agents

LANSING, Mich., March 27, 2007 /PRNewswire/ -- Afid Therapeutics, Inc. announced that it received positive results on the ability of its new triple mode viral sequestration agents to block viral infections of mammalian cells. The audited results were obtained from a specialized, independent third party testing organization. The new viral sequestrating agents are designed to bind and inactivate viruses by 3 critical mechanisms thus blocking infection. They are aimed at viruses responsible for common causes of influenza in addition to SARS, bird flu and other avian influenzas. "Carbohydrate interactions are critical to the infection process in these systems. The technology capitalizes on the companies' rich carbohydrate chemistry technology portfolio and expertise," said Afid Founder and President Rawle Hollingsworth. Dr. Hollingsworth is a world authority on carbohydrate chemistry and holds nearly 50 issued US patents, scores of international patents and well over 100 publications on many aspects of carbohydrate chemistry critical to the success of the effort. The company intends to pursue both therapeutic and non- therapeutic applications. "The chemistry can be done easily enough that applications in public health, environmental, personal care and defense arenas are well within reach," adds Hollingsworth. "There are no real obstacles to scaling up," said Dr. Li Gao, Afid's research director.

Afid Therapeutics, Inc. was the first start-up firm to receive support from the "Rational Siting Push-Pull Accelerator" (RSPPA) grant to Michigan State University (MSU) from the Michigan Technology Tri-Corridor. The company recently received a $1.66M award from the Michigan 21st Century Jobs Creation Fund. It specializes in advanced chemistry based on carbohydrates with a focus on the drug discovery and development areas and provides advanced chemical intermediates to over 50 pharmaceutical clients around the world.< /p>

CONTACT: Dr. Rawle I. Hollingsworth +1-517-336-4663, Fax +1-517-324-1912, rih@afidtherapeutics.com

Web site: http://www.afidtherapeutics.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/28/2017)... Holdings, Inc. (NYSE: HRC), will present at the Morgan Stanley ... New York . John Greisch , Hill-Rom,s ... 11:05 a.m. Eastern Time. The live audio ... replay will be available one hour after the conclusion of ... About Hill-Rom Holdings, Inc. Hill-Rom ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. ... screening tests, has received two prestigious recognitions that acknowledge the promise of its ... Preora has been named a Top 100 Finalist for the 16th annual ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand ... to detail to the athletic wear market with the launch of their FlipBelt Crops. ... have their essentials securely at their fingertips while at the gym, on the trail, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Month, Lewis and Clark College Emeritus Professor of Education Gregory A. Smith examines ... of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Coating System for clients that rely on safety and cleanliness. This unique flooring ... , Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, ...
(Date:9/20/2017)... ... ... Doctors on Liens has added the medical group Bones and Spine Surgery, ... personal injury lien basis. Founded by Dr. Wayne Cheng, MD and Dr. Gordon Yee, ... orthopedic injuries to patients in the Inland Empire. , Bones and Spines Surgery Inc ...
Breaking Medicine News(10 mins):